Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine (2 μg∙kg−1) in dogs.

de Sant'Ana Alves, Larissa; Arcoverde, Kathryn Nóbrega; de Oliveira, Caio Vinícius Almeida; Cavalcante, Jerson Marques; Araújo-Silva, Gabriel; de Paula, Valéria Veras

doi:10.1016/j.rvsc.2024.105229

Research in Veterinary Science

2024

DOI: 10.1016/j.rvsc.2024.105229

|View full text |Cite

Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine (2 μg∙kg−1) in dogs.

Larissa de Sant'Ana Alves,

Kathryn Nóbrega Arcoverde,

Caio Vinícius Almeida de Oliveira

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical Effects and Pharmacokinetic Profile of Intramuscular Dexmedetomidine (10 μg/kg) in Cats

Fernandes,

Passos,

Arcoverde

et al. 2024

Animals

View full text Add to dashboard Cite

This study investigated the pharmacokinetic profile of and pharmacodynamic response to dexmedetomidine administered intramuscularly (IM) at a dose of 10 μg/kg in healthy cats. Nine adult cats were evaluated before and after administration of the drug, with serial collections of plasma samples. Dexmedetomidine induced deep sedation, with a rapid onset of action and a duration of one hour, reaching a peak between 20 and 30 min after administration. The half-life (T½) was 70.2 ± 48 min, with a maximum concentration (Cmax) of 2.2 ± 1.9 ng/mL and time to reach maximum concentration (Tmax) of 26.4 ± 19.8 min. The area under the curve (AUC) was 167.1 ± 149.1 ng/mL*min, with a volume of distribution (Vd) of 2159.9 ± 3237.8 mL/kg and clearance (Cl) of 25.8 ± 33.0 mL/min/kg. There was a reduction in heart rate (HR) and respiratory rate (RR) in relation to the baseline, with a slight decrease in systolic (SBP), diastolic (DBP), and mean (MAP) blood pressure in the first hour. Blood glucose increased after 60 min. Dexmedetomidine proved to be effective and safe, with rapid absorption, metabolization, and elimination, promoting good sedation with minimal adverse effects after IM administration in healthy cats.

show abstract

Clinical Effects and Pharmacokinetic Profile of Intramuscular Dexmedetomidine (10 μg/kg) in Cats

Fernandes,

Passos,

Arcoverde

et al. 2024

Animals

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine (2 μg∙kg−1) in dogs.

Cited by 1 publication

References 23 publications

Clinical Effects and Pharmacokinetic Profile of Intramuscular Dexmedetomidine (10 μg/kg) in Cats

Clinical Effects and Pharmacokinetic Profile of Intramuscular Dexmedetomidine (10 μg/kg) in Cats

Contact Info

Product

Resources

About